Founded in 2002 by surgical oncologist Prof. Dr. Hartmut Juhl, Hamburg-based Indivumed GmbH is a biotech company developing precision-oncology therapeutics from patient-derived cancer data. Its clinically grounded R&D combines more than 20 years of standardized tumor-sample collection with proprietary multi-omics analysis and patient-derived tumor models to identify and validate drug targets. A global clinical network spanning North America, Europe, and Asia gives the company a broad, patient-native view of cancer biology.
Hamburg District Court HRB 81965
registration